Clinical effects of intracoronary tirofiban on preventing no-reflow during emergency percutaneous coronary intervention / 中华老年医学杂志

ABSTRACT

Objective To assess the effects of intracoronary tirofiban on preventing no-reflow during emergency percutaneous coronary intervention(PCI).Methods All 99 cases with acute myocardial infarction who underwent emergency PCI between March 2009 and March 2012 were randomized into test group of intracoronary bolus administration of tirofiban (n=50) and group of control (n =49).The clinical characteristics and the result of coronarography were observed.Thrombolysis in myocardial infarction (TIMI) flow grade,and corrected TIMI frame count (cTFC) of the two groups were compared.Incidence of 30 days follow-up major adverse cardiac events(MACE) and major bleeding events were also observed in both groups.Results Compared with control group,tirofiban treated group showed significantly more patients higher TIMI-3 flow (P＜0.05).cTFC was decreased in tirofiban treated group (21.3 ± 6.7) as compared to control group (37.6 +7.2),(P＜0.05).The incidence of no-reflow in tirofiban treated group was lower than in control.The incidence of major bleeding events were the same among two groups,while the incidence of 30 days follow-up MACE in tirofiban treared group (8％) was reduced compared with control group (18.4 ％),(P＜ 0.05).Conclusions Intracoronary tirofiban prior to emergency PCI is safe and effective for the patients with acute STEMI.It might lead to improved TIMI flow and myocardial reperfusion.